PT108.S2.Q19

PrepTest 108 - Section 2 - Question 19

Hide analysis

Newspaper editorial: Many pharmaceutical companies develop "me too" drugs, drugs designed to duplicate, more or less, the effect of another company's product that is already on the market. ████ ███████ ██████ ████ ████ ███████████ ███████████ ██ ████████████ █████████ ███ ██ █████████ ████ ████████ ██ ███ ████████ ██ ██████████ ████████ ███ █████ ██ ███ ████ █████ ████ ███ ██████ ███ ██████ ██ █ █████ █████████ ███ ███ █████ ████ █████████ ██████████ ███ ████ █████ ███ ██████ ███████ ██████████

Two Explanations

This is a weird question. It’s pretty easy if you don’t overthink it, and quite difficult if you think too much about it. I’ll explain the question through both lenses, but practically speaking you should probably just read the following, easy explanation.

Easy Mode

Don’t worry about the premise too much, since the answer choices don’t really engage with it. The conclusion says “me too” drugs can benefit consumers. The correct answer supports this conclusion by giving an example of one such benefit. The wrong answers don’t.

Ultra-Nerd Mode · (Feel Free To Skip This)

I’m not 100% sure about this, but I HEREBY ASSERT that when the stem tells us to “strengthen the argument” (as opposed to strengthening the conclusion), the correct answer must strengthen the connection between the premises and the conclusion – it can’t simply support the conclusion through totally independent means.

This question is therefore problematic, since (A) seems to do exactly that. Like wtf does (A) have to do with prices?

Nothing. But it’s still relevant to the argument’s reasoning because of the argument’s weighing factors structure. Here’s the lens we need to use:

Premise: Here’s one benefit “me too” drugs give to consumers (lower prices).
(Assumption: Factors other than price don’t outweigh this benefit to make the net effect negative.)
—
Conclusion: The overall impact of “me too” drugs is beneficial for consumers.*

So (A) does indeed present a completely different benefit these “me too” drugs offer, but that’s relevant to the reasoning because it bolsters the assumption that other factors don’t outweigh price. That is, (A) says both “sometimes ‘me too’ drugs have the additional consumer benefit of being more effective” and also “it is not the case that all these ‘me too’ drugs are horribly ineffective and actually harming consumers.”

*Note on interpreting the conclusion: To need strengthening, the arguments we find in WSE questions must be flawed. But one straightforward reading of the argument makes it seem completely valid:

Premise: Here’s one benefit “me too” drugs give to consumers (lower prices).
—
Conclusion: There is at least one benefit “me too” drugs give to consumers.

Despite being reasonable, this reading is disallowed because, again, we need an argument that has room to be strengthened. We’re therefore forced into the weighing factors reading.

Show answer
19.

Which one of the following, ██ █████ ████ ███████████ ███ ███████████ █████████

a

Some "me too" █████ ████ ███ ██ ██ ████ █████████ ████ ███ █████ ████ ████ ████████ ██ ████████

(A) directly presents an additional benefit “me too” drugs can have for consumers. In addition to lower prices, consumers also benefit from having access to more effective drugs.

91%
b

If "me too" █████ ████ ███████████ ████ █████ █████ ██ █████████ ███ ███ ███████████ ██ ██████████ ██████

Like (D), this weakens the argument by presenting a downside of “me too” drugs that could outweigh the upside of lower prices. In (B)’s world, the existence of “me too” drugs is preventing the development of future drugs, which is a bad thing for consumers.

Directionally wrong
1%
c

Pharmaceutical companies often ████ ████ █████ ██ █ ███ ████ ████ ████ ██ ██ ████████ █████

(C) presents an upside for pharmaceutical companies rather than an upside for consumers. In order for (C) to be relevant to our argument, we need to assume that “profit for pharmaceutical companies” is directly correlated with “benefits for consumers.”

This is not a reasonable assumption.

3%
d

If all pharmaceutical █████████ █████████ ███ ████ ██████ █████ ██████████ █████ █████ ██ ██████████

Like (B), this weakens the argument by presenting a downside of “me too” drugs that could outweigh the upside of lower prices. In (D)’s world, the existence of “me too” drugs may be preventing the development of future drugs, which is a bad thing for consumers.

Directionally wrong
0%
e

Some pharmaceutical companies ████ █████ ██ ███ ███████████ ██ ██████████ █████ ███████ ██ ███ ███████████ ██ █████ █████████ ██ ███ ████ ██████

There is a powerful lens through which (E) weakens the argument instead of strengthening it. Just as in (B) and (D), (E) suggests that “me too” drugs may be stifling innovation by disincentivizing the development of innovative drugs. That is, if pharmaceutical companies are losing money when they develop new drugs, they have a decreased incentive to continue innovating, which is ultimately bad for consumers.

But perhaps you think (E) strengthens the argument by corroborating the premise that “me too” drugs can result in lower prices for consumers (i.e. perhaps pharmaceutical companies are losing money because they’re being forced to charge lower prices, which is good for consumers). This interpretation of (E) is off base because premises don’t require further support. That’s what makes them premises.

Directionally wrong
Irrelevant corroboration
4%

Answer five questions and we'll estimate your score.

It takes about five minutes.

Take the free diagnostic

Confirm action

Are you sure?